Related Experiment Video

Updated: Dec 25, 2025

Extraction and Analysis of Taiwanese Green Propolis
06:50

Extraction and Analysis of Taiwanese Green Propolis

Published on: January 7, 2019

9.0K

Abietane Diterpenes as Potential Candidates for the Management of Type 2 Diabetes

Ninon G E R Etsassala1, Christopher N Cupido2, Emmanuel I Iwuoha1

  • 1Chemistry Department, University of the Western Cape, Private Bag X17, Bellville 7535, South Africa.

Current Pharmaceutical Design
|April 2, 2020
PubMed

Insights

Abietane diterpenes show promise as natural compounds for managing type 2 diabetes. This review explores their biological importance in preventing and treating this metabolic disorder.

Area of Science:

  • Pharmacology
  • Natural Product Chemistry
  • Metabolic Disorders

Background:

  • Diabetes mellitus (DM) is a prevalent metabolic disorder with significant morbidity and mortality.
  • Current treatments for type 2 diabetes have limitations including side effects and high costs.
  • Natural products offer a potential source for developing alternative antidiabetic agents.

Purpose of the Study:

  • To review the biological significance of abietane diterpenes in managing type 2 diabetes.
  • To summarize data on abietane diterpenes' role in diabetes prevention and treatment.
  • To highlight natural compounds as alternatives to synthetic antidiabetic drugs.

Main Methods:

  • Literature search of SciFinder database from 2005 to 2018.
  • Review of studies on abietane diterpenes and their biological activities.
  • Focus on data related to type 2 diabetes and associated conditions.

Main Results:

  • Abietane diterpenes exhibit diverse biological activities relevant to diabetes.
  • These compounds show potential in both prevention and management of type 2 diabetes.
  • Natural products, including abietane diterpenes, are valuable in combating metabolic diseases.

Conclusions:

  • Abietane diterpenes represent a promising class of natural compounds for type 2 diabetes therapy.
  • Further research into these compounds could lead to novel antidiabetic drug development.
  • Natural product-derived therapies offer a viable alternative for diabetes management.
Keywords:
Diabetes mellitusalkaloidsoxidative stresspolyphenolssecondary metabolitesterpenoids

More Related Videos

An In Ovo Model for Testing Insulin-mimetic Compounds06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.0K
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.6K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
757
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
531
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
785
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
487
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
464
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K